Comparison of contrast-enhanced CT, dual-layer detector spectral CT, and whole-body MRI in suspected metastatic breast cancer: a prospective diagnostic accuracy study

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30

[3] Soerjomataram I(2019)Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 30 1194-1220

[4] Siegel RL(2013)Breast cancer follow-up and management after primary treatment: American society of clinical oncology clinical practice guideline update J Clin Oncol 31 961-965

[5] Miller KD(2018)4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) Ann Oncol 29 1634-1657

[6] Jemal A(2016)Single photon emission computed tomography (SPECT) and SPECT/low-dose computerized tomography did not increase sensitivity or specificity compared to planar bone scintigraphy for detection of bone metastases in advanced breast cancer Clin Physiol Funct Imaging 36 40-46

[7] Cardoso F(2004)Bone imaging in metastatic breast cancer J Clin Oncol 22 2942-2953

[8] Kyriakides S(2016)[181F] Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in suspected recurrent breast cancer: a prospective comparative study of dual-time-point FDG-PET/CT, contrast-enhanced CT, and bone scintigraphy J Clin Oncol 34 1889-1897

[9] Ohno S(2011)Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy Eur Radiol 21 2604-2617

[10] Khatcheressian JL(2016)Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial Acta Oncol 55 59-67

[1] Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424

[2] Ferlay J(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30

[3] Soerjomataram I(2019)Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 30 1194-1220

[4] Siegel RL(2013)Breast cancer follow-up and management after primary treatment: American society of clinical oncology clinical practice guideline update J Clin Oncol 31 961-965

[5] Miller KD(2018)4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) Ann Oncol 29 1634-1657

[6] Jemal A(2016)Single photon emission computed tomography (SPECT) and SPECT/low-dose computerized tomography did not increase sensitivity or specificity compared to planar bone scintigraphy for detection of bone metastases in advanced breast cancer Clin Physiol Funct Imaging 36 40-46

[7] Cardoso F(2004)Bone imaging in metastatic breast cancer J Clin Oncol 22 2942-2953

[8] Kyriakides S(2016)[181F] Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in suspected recurrent breast cancer: a prospective comparative study of dual-time-point FDG-PET/CT, contrast-enhanced CT, and bone scintigraphy J Clin Oncol 34 1889-1897

[9] Ohno S(2011)Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy Eur Radiol 21 2604-2617

[10] Khatcheressian JL(2016)Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial Acta Oncol 55 59-67